Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
about
Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment optionsGlutamatergic drugs for schizophreniaSerine racemase binds to PICK1: potential relevance to schizophreniaEarly-stage visual processing and cortical amplification deficits in schizophrenia.Schizophrenia susceptibility gene dysbindin regulates glutamatergic and dopaminergic functions via distinctive mechanisms in DrosophilaSynthesis, SAR and unanticipated pharmacological profiles of analogues of the mGluR5 ago-potentiator ADX-47273HEGPOL: randomized, placebo controlled, multicenter, double-blind clinical trial to investigate hepatoprotective effects of glycine in the postoperative phase of liver transplantation [ISRCTN69350312].Celecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On TrialsThe impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophreniaIn vivo assessment of neurotransmitters and modulators with magnetic resonance spectroscopy: application to schizophreniaProof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophreniaMeta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophreniaA randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophreniaHas an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophreniaN[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine (NFPS) is a selective persistent inhibitor of glycine transportGABA(B) receptors, schizophrenia and sleep dysfunction: a review of the relationship and its potential clinical and therapeutic implicationsMolecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment.Allosteric modulation of metabotropic glutamate receptors.Is lead exposure in early life an environmental risk factor for Schizophrenia? Neurobiological connections and testable hypotheses.Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia.Research in people with psychosis risk syndrome: a review of the current evidence and future directionsSerine racemase is associated with schizophrenia susceptibility in humans and in a mouse model.Dysbindin-1 loss compromises NMDAR-dependent synaptic plasticity and contextual fear conditioning.GlyT-1 Inhibition Attenuates Attentional But Not Learning or Motivational Deficits of the Sp4 Hypomorphic Mouse Model Relevant to Psychiatric DisordersCognitive dysfunction in schizophrenia: unifying basic research and clinical aspects.Further characterization of the GlyT-1 inhibitor Org25935: anti-alcohol, neurobehavioral, and gene expression effects.Glycine treatment of the risk syndrome for psychosis: report of two pilot studiesIs the PANSS used correctly? a systematic review.Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study.Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs.Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain.The genetic aetiology of childhood depression: a review.From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment.The effect of risperidone on D-amino acid oxidase activity as a hypothesis for a novel mechanism of action in the treatment of schizophrenia.L-serine in disease and developmentUnderstanding antipsychotic "atypicality": a clinical and pharmacological moving targetThe sleep-promoting and hypothermic effects of glycine are mediated by NMDA receptors in the suprachiasmatic nucleusBehavioural and molecular endophenotypes in psychotic disorders reveal heritable abnormalities in glutamatergic neurotransmission.Turning a blind eye: the success of blinding reported in a random sample of randomised, placebo controlled trials.The therapeutic potential of glycine transporter-1 inhibitors.
P2860
Q22241447-79CD30AE-F6AF-49DD-8EF7-BBFCF8D217DDQ24246163-B39048CE-8B0F-4437-BE06-08DFCAF6DC8EQ24297355-6F50F647-57A5-4018-B8D4-F9D18C500951Q24536566-1C5F1F31-3F59-4729-BD71-684F656826BDQ24625434-BCF5DA37-42A2-4B43-93A8-4644FD35ABA9Q24626912-C9AF51C4-DA9C-4CD1-8D24-B0BC5BD58E9AQ24813738-85575465-6617-4163-B7CD-741FF0C51491Q26741541-68A7E6C8-252B-4E9B-ADA8-8419978E47B3Q28081110-EC07DDB5-62B8-480F-BB17-2D110BDC9458Q28083121-8E7D5604-E621-4770-8427-282580CEC44EQ28240120-D321BF48-08F5-43BE-8A83-3B86613A5906Q28248687-C01A9725-53C6-4D4F-869D-C52E2F43B65AQ28263502-0A274CB4-398F-4F77-A84F-3172596D4612Q28275290-D83D044C-D583-48E1-BE32-372B80926D4AQ28365362-BFB50BB5-28EF-446E-8E43-B2A07F1E7919Q30376372-5FFE1B58-C4B5-4B47-8194-87B4A11F40FFQ30428213-CFA95414-34B9-4143-8DF0-76CE115C35EAQ30448534-00C589F4-9DE4-450D-A90E-4DFC8754217CQ30454141-0271882E-093E-46F7-8045-3AF12CF805C7Q30473410-2C199F5B-6EC2-4646-8400-B60ED36E5FDAQ30475598-92E848F5-FC45-4335-941A-1E5B029F0E85Q30479725-BCF7710B-F521-4B54-BCDB-80867D635291Q30573050-1A4FB4E7-4A1D-470A-8585-6B0C60ED637CQ30756194-5772B14F-3446-4251-8DF1-D2E05F9D9139Q33179619-339A74D9-8E54-4736-AFB6-C24BC1E5E98BQ33586550-8C67BF03-6243-4D37-B852-607684E398FAQ33637911-C97AD385-8192-4285-A99F-11F8F90928C9Q33964357-078A9B83-8070-4F87-80DF-7215DFD9F75BQ34013820-184BA864-5EF1-433E-A0F6-DFD8701DE032Q34338202-54CD83EF-5CF4-4865-9213-5D66DCB09EFDQ34381226-B53E54FD-5F2C-4DBF-99F8-ED9B2E6B3B2EQ34521137-A9C3A721-21CA-4D7F-AF36-CF370718A2F4Q34632695-A817902C-F728-433B-B10C-D602211D30DBQ34970798-014584E0-92F5-4D2A-AC5E-B7F6F9573E03Q35048045-73AF50B9-EF79-448E-BAAB-1326CDDE211DQ35200831-3B974063-A373-40BE-BC27-5E7D194EA3D8Q35421051-DDC29F3C-3008-4FDC-9ADB-17396F3A6AB4Q35598785-350A3D9F-B3C2-451E-8CAC-EAD67A85EDECQ35648461-9C8E67B8-6C26-40E6-8176-109D0E2CCD55Q35779254-2ACAE047-E714-4295-8903-D2D6DFFB9F29
P2860
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Efficacy of high-dose glycine ...... ive symptoms of schizophrenia.
@ast
Efficacy of high-dose glycine ...... ive symptoms of schizophrenia.
@en
Efficacy of high-dose glycine ...... ive symptoms of schizophrenia.
@nl
type
label
Efficacy of high-dose glycine ...... ive symptoms of schizophrenia.
@ast
Efficacy of high-dose glycine ...... ive symptoms of schizophrenia.
@en
Efficacy of high-dose glycine ...... ive symptoms of schizophrenia.
@nl
prefLabel
Efficacy of high-dose glycine ...... ive symptoms of schizophrenia.
@ast
Efficacy of high-dose glycine ...... ive symptoms of schizophrenia.
@en
Efficacy of high-dose glycine ...... ive symptoms of schizophrenia.
@nl
P2093
P356
P1433
P1476
Efficacy of high-dose glycine ...... ive symptoms of schizophrenia.
@en
P2093
Heresco-Levy U
Lichtenstein M
P356
10.1001/ARCHPSYC.56.1.29
P407
P577
1999-01-01T00:00:00Z